$XNCR News

Xencor (XNCR) Is Up 15.8% What's Changed After Kidney Cancer Trial Update

Xencor Catapults On 'Unprecedented,' 'Profound' Cancer Data

Xencor Picks Phase 3 Dose After XmAb819 Shows 45.5% Response Rate in Kidney Cancer

Xencor Soars 31% on Kidney Cancer Trial Data Showing “Impressive Antitumor Activity”

Xencor shares jump as kidney cancer drug data support Phase 3 plans

Xencor: 'Strong Buy' On Positive XmAb819 ESMO Data ccRCC And Potential For FDA Accelerated Approval Pathway

Xencor stock surges on positive cancer drug trial data

Xencor Catapults, Breaking Out On 'Unprecedented,' 'Profound' Cancer Data

Xencor, Inc. (XNCR) Discusses Phase 1 XmAb819 Results in Advanced Clear Cell Renal Cell Carcinoma Transcript

Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors

Wedbush Reiterates Outperform on Xencor, Maintains $30 Price Target

Is Xencor (XNCR) A Bargain After Its XmAb819 Phase 1 Update?

Xencor to Host Webcast to Discuss Results From the Phase 1 Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma

Xencor: Better Funding For Obexelimab

Truist Securities Reiterates Buy on Xencor, Raises Price Target to $29

B of A Securities Maintains Neutral on Xencor, Raises Price Target to $26

Barclays Maintains Overweight on Xencor, Raises Price Target to $35

JP Morgan Maintains Neutral on Xencor, Raises Price Target to $21

Xencor to Present at the 2026 Cantor Global Healthcare Conference

Raymond James Maintains Strong Buy on Xencor, Raises Price Target to $46